loading
Neurocrine Biosciences Inc stock is traded at $126.55, with a volume of 1.58M. It is down -0.60% in the last 24 hours and up +2.92% over the past month. Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$127.31
Open:
$127.88
24h Volume:
1.58M
Relative Volume:
1.12
Market Cap:
$12.29B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
42.90
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
+1.74%
1M Performance:
+2.92%
6M Performance:
-6.55%
1Y Performance:
-5.61%
1-Day Range:
Value
$125.53
$128.38
1-Week Range:
Value
$123.12
$128.38
52-Week Range:
Value
$84.23
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Name
Neurocrine Biosciences Inc
Name
Phone
(858) 617-7600
Name
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Employee
1,800
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
NBIX's Discussions on Twitter

Compare NBIX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
126.55 12.29B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
38.01 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
157.17 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.41 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.77 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.95 20.17B 16.54B -1.64B 749.00M -1.45

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-25 Upgrade Needham Hold → Buy
Apr-14-25 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-11-25 Initiated Deutsche Bank Hold
Oct-10-24 Resumed Raymond James Outperform
Aug-29-24 Upgrade Piper Sandler Neutral → Overweight
Apr-24-24 Upgrade Wells Fargo Equal Weight → Overweight
Dec-13-23 Resumed Citigroup Neutral
Dec-12-23 Initiated Deutsche Bank Buy
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Aug-21-23 Reiterated Mizuho Neutral
Jul-24-23 Upgrade SVB Securities Market Perform → Outperform
Jul-06-23 Upgrade BMO Capital Markets Underperform → Market Perform
May-04-23 Upgrade Guggenheim Neutral → Buy
Mar-30-23 Upgrade Canaccord Genuity Hold → Buy
Mar-03-23 Upgrade Evercore ISI In-line → Outperform
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-14-22 Downgrade Evercore ISI Outperform → In-line
Oct-11-22 Initiated UBS Buy
Sep-26-22 Initiated Wells Fargo Equal Weight
Jun-06-22 Resumed Jefferies Buy
Mar-03-22 Downgrade Piper Sandler Overweight → Neutral
Feb-25-22 Upgrade Goldman Neutral → Buy
Jan-18-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-21 Initiated BMO Capital Markets Underperform
Nov-17-21 Upgrade JP Morgan Neutral → Overweight
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Aug-06-21 Downgrade Canaccord Genuity Buy → Hold
May-18-21 Resumed Goldman Neutral
May-06-21 Upgrade Barclays Equal Weight → Overweight
Feb-02-21 Initiated Raymond James Outperform
Sep-30-20 Initiated The Benchmark Company Hold
Aug-04-20 Downgrade JP Morgan Overweight → Neutral
Jun-29-20 Downgrade Goldman Buy → Neutral
Jun-09-20 Initiated Wedbush Outperform
Mar-06-20 Initiated Citigroup Buy
Feb-27-20 Initiated Barclays Equal Weight
Feb-24-20 Initiated William Blair Outperform
Feb-06-20 Initiated Mizuho Neutral
Feb-05-20 Reiterated H.C. Wainwright Buy
Dec-13-19 Downgrade Credit Suisse Outperform → Neutral
Aug-07-19 Initiated RBC Capital Mkts Outperform
Jul-16-19 Initiated Oppenheimer Outperform
Jun-05-19 Initiated Guggenheim Neutral
May-21-19 Initiated Credit Suisse Outperform
Apr-22-19 Upgrade JP Morgan Neutral → Overweight
Apr-12-19 Initiated Evercore ISI Outperform
Feb-06-19 Reiterated BofA/Merrill Buy
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Dec-13-18 Initiated Goldman Buy
Nov-21-18 Initiated Canaccord Genuity Buy
View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

pulisher
Jun 16, 2025

Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting - MSN

Jun 16, 2025
pulisher
Jun 14, 2025

Neurocrine Biosciences’ SWOT analysis: biotech stock balances Ingrezza success with pipeline potential - Investing.com

Jun 14, 2025
pulisher
Jun 12, 2025

Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com

Jun 12, 2025
pulisher
Jun 11, 2025

Endometriosis Market on Track for Major Expansion by 2034, - openPR.com

Jun 11, 2025
pulisher
Jun 10, 2025

Neurocrine Loses Suit Challenging Hormone Treatment Patent - Law360

Jun 10, 2025
pulisher
Jun 10, 2025

Judge Tosses Neurocrine’s Suit Over Spruce Hormone-Drug Patent - Bloomberg Law News

Jun 10, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences names new Chief Information Officer By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer - The Malaysian Reserve

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences (NBIX) Appoints Lewis Choi as CIO | NBIX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences Names Lewis Choi as Chief Information Officer - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Endometriosis Pain Pipeline 2025: Mechanism of Action, Route - openPR.com

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences (NBIX) Appoints Lewis Choi as Chief Information Officer - StreetInsider

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences names new Chief Information Officer - Investing.com

Jun 09, 2025
pulisher
Jun 05, 2025

Congenital Adrenal Hyperplasia Market Growth Projections - openPR.com

Jun 05, 2025
pulisher
Jun 03, 2025

(NBIX) Technical Data - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

Nxera earns $15 million as Neurocrine advances schizophrenia drug - The Pharma Letter

Jun 03, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences Projects Strong Ingrezza Sales For 2025 - Finimize

Jun 02, 2025
pulisher
Jun 02, 2025

Nxera Pharma to Receive US$15 Million from Neurocrine - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - GlobeNewswire Inc.

Jun 02, 2025
pulisher
Jun 02, 2025

Analyst Expectations For Neurocrine Biosciences's Future - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

RBC Capital Reiterates Outperform Rating for Neurocrine Biosciences (NBIX) | NBIX Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences Announces Phase 4 KINECT-PRO Data - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

[Latest] USA Tardive Dyskinesia Treatment Market: New Drugs, - openPR.com

Jun 02, 2025
pulisher
Jun 02, 2025

Neurocrine (NBIX) Reports Positive Results from INGREZZA Study on Tardive Dyskinesia | NBIX Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Groundbreaking INGREZZA Study Reveals Life-Changing Benefits for Tardive Dyskinesia Patients in Just 4 Weeks - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - Quantisnow

Jun 01, 2025
pulisher
May 30, 2025

Huntington's Disease Society hosts Team Hope Walk in Tulsa Saturday - KTUL

May 30, 2025
pulisher
May 30, 2025

Director Kevin Gorman Sells 9,613 Shares of Neurocrine Biosciences Inc (NBIX) - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched - MSN

May 30, 2025
pulisher
May 30, 2025

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III - insights.citeline.com

May 30, 2025
pulisher
May 29, 2025

Neurocrine Biosciences director sells shares worth $1.16 million By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Neurocrine Biosciences director sells shares worth $1.16 million - Investing.com

May 29, 2025
pulisher
May 29, 2025

Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophr - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff - Endpoints News

May 29, 2025
pulisher
May 29, 2025

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - The Malaysian Reserve

May 29, 2025
pulisher
May 28, 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophrenia Treatment | NBIX Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Neurocrine reports positive Phase 2 schizophrenia study results - Investing.com

May 28, 2025
pulisher
May 28, 2025

Neurocrine reports positive Phase 2 schizophrenia study results By Investing.com - Investing.com UK

May 28, 2025
pulisher
May 25, 2025

Neurocrine Biosciences’ SWOT analysis: stock’s resilience amid market challenges - Investing.com Australia

May 25, 2025
pulisher
May 24, 2025

How to Take Advantage of moves in (NBIX) - news.stocktradersdaily.com

May 24, 2025
pulisher
May 23, 2025

Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Nasdaq

May 23, 2025
pulisher
May 23, 2025

Cetera Investment Advisers Purchases 2,593 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World

May 23, 2025
pulisher
May 20, 2025

Neurocrine at RBC Conference: Growth and Strategic Insights - Investing.com

May 20, 2025
pulisher
May 20, 2025

Transcript : Neurocrine Biosciences, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 11 - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourette Syndrome Treatment Market Detailed Analysis - openPR.com

May 20, 2025
pulisher
May 17, 2025

Neurocrine Biosciences (NBIX) Shares Positive Results from Pedia - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Neurocrine reports quality of life gains in tardive dyskinesia study By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Neurocrine Presents Encouraging New Data From Phase 4 Study Of Ingrezza In Tardive Dyskinesia - Nasdaq

May 16, 2025

Neurocrine Biosciences Inc Stock (NBIX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$290.75
price down icon 0.33%
drug_manufacturers_specialty_generic RDY
$15.23
price up icon 0.26%
$8.87
price up icon 1.14%
$13.46
price up icon 0.98%
$16.95
price down icon 0.64%
Cap:     |  Volume (24h):